The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management.

The dysplastic nevus is a discreet histologic entity that exhibits some clinical and histologic features overlapping with common nevi and melanoma. These overlapping features present a therapeutic challenge, and with a lack of accepted guidelines, the management of dysplastic nevi remains a controversial subject. Although some differences between dysplastic and common nevi can be detected at the molecular level, there are currently no established markers to predict biologic behavior. In part II of this continuing medical education article, we will review the molecular aspects of dysplastic nevi and their therapeutic implications. Our goal is to provide the clinician with an up-to-date understanding of this entity to facilitate clinical management of patients with nevi that have histologic dysplasia.

[1]  D. Bennett Human melanocyte senescence and melanoma susceptibility genes , 2003, Oncogene.

[2]  S. Leachman,et al.  Response to Gray-Schopfer et al. and Michaloglou et al. , 2008 .

[3]  A. Marghoob,et al.  Treatment of dysplastic nevi with 5% imiquimod cream, a pilot study. , 2006, Journal of drugs in dermatology : JDD.

[4]  D. Margolis,et al.  Variability in nomenclature used for nevi with architectural disorder and cytologic atypia (microscopically dysplastic nevi) by dermatologists and dermatopathologists , 2004, Journal of cutaneous pathology.

[5]  W. Westra,et al.  Distribution of BRAF T1799A(V600E) Mutations Across Various Types of Benign Nevi: Implications for Melanocytic Tumorigenesis , 2007, The American Journal of dermatopathology.

[6]  S. Cramer War and peace in the Realm of Dysplastic Nevi , 2005, Journal of cutaneous pathology.

[7]  M. Shoup,et al.  Predictors of positive sentinel lymph node in thin melanoma. , 2011, American journal of surgery.

[8]  K. Arndt,et al.  Laser treatment of pigmented lesions--2000: how far have we gone? , 2000, Archives of dermatology.

[9]  T. Spector,et al.  Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi , 2009, Nature Genetics.

[10]  F. Meyskens,et al.  Effect of oral isotretinoin on dysplastic nevi. , 1989, Journal of the American Academy of Dermatology.

[11]  M. Martinka,et al.  Prognostic significance of RUNX3 expression in human melanoma , 2011, Cancer.

[12]  W. Clark,et al.  Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. , 1978, Archives of dermatology.

[13]  S. Florell,et al.  Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi , 2005, Journal of cutaneous pathology.

[14]  W. Clark,et al.  Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1p, and evidence for genetic heterogeneity. , 1993, American journal of human genetics.

[15]  N. Hayward,et al.  A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation , 2005, Genes, chromosomes & cancer.

[16]  A. Marghoob,et al.  Management of dysplastic nevi: a survey of fellows of the American Academy of Dermatology. , 2002, Journal of the American Academy of Dermatology.

[17]  M. Martinka,et al.  Treatment of atypical nevi with imiquimod 5% cream. , 2007, Archives of dermatology.

[18]  A. H. Diwan,et al.  Phosphoinositide 3‐kinase is not overexpressed in melanocytic lesions , 2007, Journal of cutaneous pathology.

[19]  A. Elefanty,et al.  Human acquired naevi are clonal , 1998, Melanoma research.

[20]  G. Botti,et al.  Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma , 2007, The British journal of dermatology.

[21]  A. Wojas-Pelc,et al.  Cyclin D1 and D3 expression in melanocytic skin lesions , 2010, Archives of Dermatological Research.

[22]  S. H. Kim,et al.  Genetic alterations of p16INK4a and p53 genes in sporadic dysplastic nevus. , 1997, Biochemical and biophysical research communications.

[23]  G. Screaton,et al.  Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand. , 2006, Human pathology.

[24]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.

[25]  J. Simon,et al.  A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[26]  C. Lewis,et al.  A multiobserver, population-based analysis of histologic dysplasia in melanocytic nevi. , 1994, Journal of the American Academy of Dermatology.

[27]  P. Green,et al.  Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. , 1989, The New England journal of medicine.

[28]  B. Bates With Dysplastic Nevi, Pause Before You Biopsy , 2006 .

[29]  A. Kopf What Is Early Melanoma? , 1993, The American Journal of dermatopathology.

[30]  D. Pinkel,et al.  Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. , 2000, The American journal of pathology.

[31]  G. Annessi,et al.  Correlation between clinical atypia and histologic dysplasia in acquired melanocytic nevi. , 2001, Journal of the American Academy of Dermatology.

[32]  D. Grossman,et al.  Strategies for early melanoma detection: Approaches to the patient with nevi. , 2009, Journal of the American Academy of Dermatology.

[33]  W. Clark,et al.  Lack of association between intraocular melanoma and cutaneous dysplastic nevi. , 1984, American journal of ophthalmology.

[34]  C. Sherr Cancer Cell Cycles , 1996, Science.

[35]  D. Barnes,et al.  p53 immunoreactivity in human malignant melanoma and dysplastic naevi , 1993, The British journal of dermatology.

[36]  T. Venesio,et al.  Altered molecular pathways in melanocytic lesions , 2010, International journal of cancer.

[37]  P. Duray,et al.  Loss of heterozygosity detected on 1p and 9q in microdissected atypical nevi. , 1998, Archives of dermatology.

[38]  Michael R. Green,et al.  Role for IGFBP7 in Senescence Induction by BRAF , 2010, Cell.

[39]  R. Barr,et al.  Histologic atypia in clinically benign nevi. A prospective study. , 1990, Journal of the American Academy of Dermatology.

[40]  R. Anderson,et al.  Treatment of benign and atypical nevi with the normal-mode ruby laser and the Q-switched ruby laser: clinical improvement but failure to completely eliminate nevomelanocytes. , 1999, Archives of dermatology.

[41]  S. Cessie,et al.  Effect of topical tretinoin under occlusion on atypical naevi , 1998, Melanoma research.

[42]  W. Clark,et al.  National Institutes of Health Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma, January 27–29, 1992 , 1993 .

[43]  M. Hurt The melanocytic nevus described by Clark et al. What is its nature? What should it be named? An answer from history and from logic , 2005, Journal of cutaneous pathology.

[44]  W. Bergman,et al.  Ocular melanoma in families with dysplastic nevus syndrome. , 1990, Journal of the American Academy of Dermatology.

[45]  B. Lebe,et al.  The Significance of Ki-67 Proliferative Index and Cyclin D1 Expression of Dysplastic Nevi in the Biologic Spectrum of Melanocytic Lesions , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[46]  W. Clark,et al.  Topical chemotherapy of dysplastic melanocytic nevi with 5% fluorouracil. , 1981, Archives of dermatology.

[47]  Michael R. Green,et al.  Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7--challenging the concept of dysplastic nevi as precursor lesions? , 2010, Human pathology.

[48]  S. Leachman,et al.  Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo. , 2007, The Journal of investigative dermatology.

[49]  G. Enders,et al.  p16INK4a can initiate an autonomous senescence program , 2000, Oncogene.

[50]  M. Piepkorn,et al.  Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions. , 1998, The Journal of investigative dermatology.

[51]  G. Wood,et al.  Comprehensive analysis of 112 melanocytic skin lesions demonstrates microsatellite instability in melanomas and dysplastic nevi, but not in benign nevi , 2001, Journal of cutaneous pathology.

[52]  A. Ackerman,et al.  Pseudomelanoma: recurrent melanocytic nevus following partial surgical removal. , 1975, Archives of dermatology.

[53]  T. Batinac,et al.  Expression of cell cycle and apoptosis regulatory proteins and telomerase in melanocitic lesions. , 2007, Collegium antropologicum.

[54]  D. Levin,et al.  Detection of p53 mutations in benign and dysplastic nevi. , 1995, Cancer research.

[55]  M. van de Rijn,et al.  bcl-2 expression in melanocytic nevi. Insights into the biology of dermal maturation. , 1995, Archives of dermatology.

[56]  J. Becker,et al.  Germline mutations in BAP1 predispose to melanocytic tumors , 2011, Nature Genetics.

[57]  T. Alanko,et al.  FGF expression allows nevus cells to survive in three-dimensional collagen gel under conditions that induce apoptosis in normal human melanocytes. , 1999, The Journal of investigative dermatology.

[58]  W. Clark,et al.  A natural history of melanomas and dysplastic nevi , 2002, Cancer.

[59]  R. Presland,et al.  A search for CDKN2A/p16INK4a mutations in melanocytic nevi from patients with melanoma and spouse controls by use of laser-captured microdissection. , 2005, Archives of dermatology.

[60]  W. Clark,et al.  Two-locus linkage analysis of cutaneous malignant melanoma/dysplastic nevi. , 1996, American journal of human genetics.

[61]  D. Bennett,et al.  Comment on "Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo". , 2008, The Journal of investigative dermatology.

[62]  C. Bartoli,et al.  Detection of microsatellite alterations in the spectrum of melanocytic nevi in patients with or without individual or family history of melanoma , 2000, International journal of cancer.

[63]  Michael R. Green,et al.  Oncogenic BRAF Induces Senescence and Apoptosis through Pathways Mediated by the Secreted Protein IGFBP7 , 2008, Cell.

[64]  E. R. Farmer,et al.  NIH Consensus conference. Diagnosis and treatment of early melanoma. , 1992, JAMA.

[65]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[66]  J. Naeyaert,et al.  Inter‐observer variation in the histopathological diagnosis of clinically suspicious pigmented skin lesions , 2002, The Journal of pathology.

[67]  N. Smit,et al.  Increased Melanogenesis is a Risk Factor for Oxidative DNA Damage— Study on Cultured Melanocytes and Atypical Nevus Cells † , 2008, Photochemistry and photobiology.

[68]  H. Ananthaswamy,et al.  P53 protein and pathogenesis of melanoma and nonmelanoma skin cancer. , 2008, Advances in experimental medicine and biology.

[69]  D. Pinkel,et al.  Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. , 2007, The Journal of investigative dermatology.

[70]  J. Kelly,et al.  A high incidence of melanoma found in patients with multiple dysplastic naevi by photographic surveillance , 1997, The Medical journal of Australia.

[71]  F. Kiesewetter,et al.  Differentiation between Spitz nevi and malignant melanomas by interphase fluorescence in situ hybridization. , 1999, International journal of oncology.

[72]  P. Uribe,et al.  Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi. , 2006, The Journal of investigative dermatology.

[73]  R. Parsons,et al.  The role of PTEN signaling perturbations in cancer and in targeted therapy , 2008, Oncogene.

[74]  L. Liotta,et al.  Allelic deletion at chromosome 9p21(p16) and 17p13(p53) in microdissected sporadic dysplastic nevus. , 1998, Human pathology.

[75]  J. Radhi Malignant Melanoma Arising from Nevi, p53, p16, and Bcl-2: Expression in Benign versus Malignant Components , 1999, Journal of cutaneous medicine and surgery.

[76]  R. Marais,et al.  Cellular senescence in naevi and immortalisation in melanoma: a role for p16? , 2006, British Journal of Cancer.

[77]  R. Barr,et al.  Analysis of heterogeneity of atypia within melanocytic nevi. , 2003, Archives of dermatology.

[78]  Yu Fang,et al.  Fluorescence in Situ Hybridization for Distinguishing Nevoid Melanomas From Mitotically Active Nevi , 2009, The American journal of surgical pathology.

[79]  John Calvin Reed,et al.  Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma. , 1995, The American journal of pathology.

[80]  Gary S. Rogers,et al.  Diagnosis and Treatment of Early Melanoma: NIH Consensus Development Panel on Early Melanoma , 1992 .

[81]  D. Weiss,et al.  Mutational analysis of N-ras, p53, CDKN2A (p16INK4a), p14ARF, CDK4, and MC1R genes in human dysplastic melanocytic naevi , 2003, Journal of medical genetics.

[82]  M. Nasr,et al.  Comparison of pHH3, Ki-67, and Survivin Immunoreactivity in Benign and Malignant Melanocytic Lesions , 2008, The American Journal of dermatopathology.

[83]  T. Papp,et al.  Mutational analysis of the BRAF gene in human congenital and dysplastic melanocytic naevi , 2005, Melanoma research.

[84]  H. Breuninger,et al.  Dysplastic nevus syndrome with development of multiple melanomas. A surgical concept for prophylaxis , 2009, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[85]  A Halpern,et al.  Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. , 1997, JAMA.

[86]  H. Koerten,et al.  Disturbed melanin synthesis and chronic oxidative stress in dysplastic naevi. , 2004, European journal of cancer.

[87]  J. Shay,et al.  BRAFE600-associated senescence-like cell cycle arrest of human naevi , 2005, Nature.

[88]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[89]  Ackerman Ab A critique of an N.I.H. Consensus Development Conference about "early" melanoma. , 1993 .

[90]  C. Shea,et al.  Clinical decision making based on histopathologic grading and margin status of dysplastic nevi. , 2012, Archives of dermatology.

[91]  J. McNiff,et al.  Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. , 1999, The Journal of investigative dermatology.

[92]  D. Peeper,et al.  Oncogene-induced cell senescence--halting on the road to cancer. , 2006, The New England journal of medicine.

[93]  M. Mihm,et al.  PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma. , 2003, Journal of the American Academy of Dermatology.

[94]  D. Peeper,et al.  Comment on "Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo". , 2008, The Journal of investigative dermatology.

[95]  S. Florell,et al.  Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi. , 2010, Journal of the American Academy of Dermatology.

[96]  A. Emley,et al.  BRAF V600E mutation and the tumour suppressor IGFBP7 in atypical genital naevi , 2010, The British journal of dermatology.

[97]  E. Glusac What to call the LEJC‐BFV nevus? , 2004, Journal of cutaneous pathology.

[98]  J. Grichnik Dermoscopy of melanocytic neoplasms: subpatterns of dysplastic/atypical nevi. , 2003, Archives of dermatology.

[99]  D. Massi,et al.  A new concept of melanocytic neoplasia pathogenesis based on the phenotype of common acquired nevi. , 2007, Medical hypotheses.

[100]  M. Mihm,et al.  Recurrent nevus phenomenon: a clinicopathologic study of 357 cases and histologic comparison with melanoma with regression , 2009, Modern Pathology.

[101]  I. Newsham,et al.  Alteration of chromosome 9p21 and/or p16 in benign and dysplastic nevi suggests a role in early melanoma progression (United States) , 2002, Cancer Causes & Control.